This observational, multicenter study will assess the efficacy and safety of Herceptin (trastuzumab) in routine clinical practice in patients with HER2-positive advanced adenocarcinoma of the stomach or gastro-esophageal junction. Data from patients will be collected for approximately 12 months.
Study Type
OBSERVATIONAL
Enrollment
443
Krankenhaus Nordwest; Klinik f. Onkologie und Hämatologie
Frankfurt, Germany
Response rate according to Response Evaluation Criteria in Solid Tumors (RECIST)
Time frame: 12 months
Progression-free survival according to Response Evaluation Criteria in Solid Tumors (RECIST)
Time frame: 12 months
Overall survival according to Response Evaluation Criteria in Solid Tumors (RECIST)
Time frame: 12 months
Documentation of the testing process for HER2-positive tumors
Time frame: 12 months
Assessment of implementation of guidelines and recommendations of Herceptin administration in routine clinical practice
Time frame: 12 months
Documentation of backbone chemotherapy treatment and concomitant medication
Time frame: 12 months
Quality of Life questionnaire
Time frame: 12 months
Surveillance of pain intensity and analgesic consumption
Time frame: 12 months
Surveillance of weight change
Time frame: 12 months
Safety (incidence of adverse events)
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.